Pipeline
Our pipeline
Our soluble TCR-based therapies hold the potential to transform the lives of people living with cancer and a wide spectrum of immune-mediated diseases. Leveraging our platform technologies, we are rapidly advancing a robust and differentiated pipeline of specificity- and affinity-enhanced soluble TCR engagers for accelerated clinical impact.
Our lead assets
ENGI-003
ENGI-003 is a trispecific specTR targeting glypican-3 (GPC3), a protein expressed in over 70% of hepatocellular carcinoma (HCC) tumours. Current treatments for HCC have limited efficiency and durability of responses, leaving up to half of patients with few alternative treatment options.
Recognizing that T cell exhaustion is an important challenge presented by the immunosuppressive tumour microenviroment of HCC tumours, ENGI-003 is focused on promoting T cell fitness by leveraging specTR trispecific technology and is expected to enter clinical studies in 2026.
ENGI-004
ENGI-004 is an inhibitory specTR (inspecTR) that targets an MHC-related receptor overexpressed at barrier sites of the human body, such as the skin and the gut. ENGI-004 is being developed to treat inflammatory conditions affecting these tissues, including atopic dermatitis (eczema) and ulcerative colitis.
By specifically targeting inflamed tissues, ENGI-004 is designed to deliver potent inhibitory signals at the relevant site for enhanced efficacy and safety. We are deploying our advanced AI-guided protein engineering platforms to rapidly progress ENGI-004 through its discovery stage and expect to enter clinical studies in 2027.